Lorlatinib
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Conditions
Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Trial Timeline
May 27, 2022 → May 1, 2026
NCT ID
NCT05297890About Lorlatinib
Lorlatinib is a phase 2 stage product being developed by Pfizer for Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05297890. Target conditions include Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03127618 | Pre-clinical | Completed |
| NCT03178071 | Pre-clinical | Completed |
| NCT06678555 | Pre-clinical | Active |
| NCT06487078 | Pre-clinical | Recruiting |
| NCT05297890 | Phase 2 | Active |
| NCT05224609 | Phase 1 | Completed |
| NCT05144997 | Approved | Active |
| NCT04753658 | Pre-clinical | Terminated |
| NCT04362072 | Approved | Completed |
| NCT04541706 | Approved | Completed |
| NCT06282991 | Pre-clinical | Completed |
| NCT03909971 | Phase 2 | Completed |
| NCT03542305 | Phase 1 | Completed |
| NCT03505554 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer